The Swiss Investment Fund for Emerging Markets (SIFEM) is the development finance institution of the Swiss Confederation and a cornerstone of Swiss development cooperation. The purpose and basic mandate are described in the Ordinance on International Development Cooperation and Humanitarian Aid as well as in the Ordinance on Cooperation with the States of Eastern Europe. SIFEM was established in 2005 and took over the investment portfolio of SECO (State Secretariat for Economic Affairs) which had been built up since the late 1990s.
Contact
SIFEM AG, c/o Obviam DFI AG
Bubenbergplatz 11
3011 Bern
Switzerland
Phone +41 (0)31 310 09 30
Telefax +41 (0)31 310 09 39
www.sifem.ch
One of the doyens of European biotech is stepping back from general management. Jean-Paul Clozel founded rare disease focused Actelion along with his wife Martine Clozel in 1997, a company…
The latest news from Swiss pharma and biotech including a new CEO appointment for leading CDMO Lonza, promising Phase III readouts from Novartis’ latest leukaemia drug at ASCO, Roche’s pivot…
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over…
Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its…
See our Cookie Privacy Policy Here
